IL148964A0 - Piperazine compounds - Google Patents

Piperazine compounds

Info

Publication number: IL148964A0
Authority: IL; Israel
Prior art keywords: piperazine compounds; piperazine; compounds
Prior art date: 1999-10-07

Application number

IL14896400A

Other languages

English (en)

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-10-07

Filing date

2000-10-05

Publication date

2002-11-10

2000-10-05 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2002-11-10 Publication of IL148964A0 publication Critical patent/IL148964A0/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Epidemiology (AREA)
Psychiatry (AREA)
Addiction (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Pulmonology (AREA)
Rheumatology (AREA)
Otolaryngology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Hydrogenated Pyridines (AREA)

IL14896400A 1999-10-07 2000-10-05 Piperazine compounds IL148964A0 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9923748.9A GB9923748D0 (en)	1999-10-07	1999-10-07	Chemical compounds
PCT/EP2000/009722 WO2001025219A2 (en)	1999-10-07	2000-10-05	Piperazine compounds

Publications (1)

Publication Number	Publication Date
IL148964A0 true IL148964A0 (en)	2002-11-10

Family

ID=10862304

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
IL14896400A IL148964A0 (en)	1999-10-07	2000-10-05	Piperazine compounds
IL148964A IL148964A (en)	1999-10-07	2002-04-01	Compounds of piperazine

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
IL148964A IL148964A (en)	1999-10-07	2002-04-01	Compounds of piperazine

Country Status (33)

Country	Link
US (6)	US6951861B1 (el)
EP (3)	EP1460066B1 (el)
JP (1)	JP4776844B2 (el)
KR (2)	KR100857671B1 (el)
CN (1)	CN100413850C (el)
AR (2)	AR025975A1 (el)
AT (3)	ATE270664T1 (el)
AU (1)	AU768780B2 (el)
BR (1)	BR0014541A (el)
CA (1)	CA2386515C (el)
CO (1)	CO5251467A1 (el)
CY (2)	CY1110172T1 (el)
CZ (1)	CZ302340B6 (el)
DE (3)	DE60040176D1 (el)
DK (3)	DK1460066T3 (el)
ES (3)	ES2222927T3 (el)
GB (1)	GB9923748D0 (el)
HK (3)	HK1052506B (el)
HU (1)	HUP0203136A3 (el)
IL (2)	IL148964A0 (el)
MX (1)	MXPA02003515A (el)
MY (1)	MY130907A (el)
NO (1)	NO323776B1 (el)
NZ (2)	NZ531127A (el)
PE (1)	PE20010741A1 (el)
PL (1)	PL201191B1 (el)
PT (3)	PT1460066E (el)
SI (3)	SI1454901T1 (el)
TN (1)	TNSN00194A1 (el)
TR (1)	TR200200936T2 (el)
TW (1)	TWI225485B (el)
WO (1)	WO2001025219A2 (el)
ZA (1)	ZA200202589B (el)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2002537245A (ja) *	1999-02-18	2002-11-05	ノバルティスアクチエンゲゼルシャフト	５−ｈｔ３レセプターアンタゴニストの使用
USRE39921E1 (en)	1999-10-07	2007-11-13	Smithkline Beecham Corporation	Chemical compounds
GB9923748D0 (en) *	1999-10-07	1999-12-08	Glaxo Group Ltd	Chemical compounds
AUPQ514600A0 (en)	2000-01-18	2000-02-10	James Cook University	Brain injury treatment
GB0003232D0 (en) *	2000-02-11	2000-04-05	Smithkline Beecham Plc	Novel composition
GB0025354D0 (en)	2000-10-17	2000-11-29	Glaxo Group Ltd	Chemical compounds
GB0108595D0 (en) *	2001-04-05	2001-05-23	Glaxo Group Ltd	Chemical compounds
GB0108594D0 (en) *	2001-04-05	2001-05-23	Glaxo Group Ltd	Chemical compounds
US20030083345A1 (en) *	2001-07-10	2003-05-01	Torsten Hoffmann	Method of treatment and/or prevention of brain, spinal or nerve injury
GB0119797D0 (en) *	2001-08-14	2001-10-03	Glaxo Group Ltd	Chemical compounds
GB0124463D0 (en)	2001-10-11	2001-12-05	Smithkline Beecham Plc	Compounds
GB0203020D0 (en) *	2002-02-08	2002-03-27	Glaxo Group Ltd	Chemical compounds
JP2005522436A (ja)	2002-02-08	2005-07-28	グラクソ　グループ　リミテッド	ピペリジルカルボキシアミド誘導体またはそのタキキニン介在疾患の治療における使用
GB0203022D0 (en)	2002-02-08	2002-03-27	Glaxo Group Ltd	Chemical compounds
DE10209145A1 (de) *	2002-03-01	2003-09-04	Bayer Cropscience Ag	Halogenbenzole
EP1556054A4 (en) *	2002-05-29	2007-09-05	Univ California	ANTAGONIZING NK1 RECEPTORS RESTRICT DRUG ABUSE
JP4079727B2 (ja) *	2002-09-06	2008-04-23	セントラル硝子株式会社	光学活性１−（フルオロ、トリフルオロメチルまたはトリフルオロメトキシ置換フェニル）アルキルアミンｎ−モノアルキル誘導体とその製造方法
WO2004067093A2 (en) *	2003-01-27	2004-08-12	Glaxo Group Limited	Nk1 receptor antagonists for the treatment of functional dyspepsia
GB0308968D0 (en) *	2003-04-17	2003-05-28	Glaxo Group Ltd	Medicaments
JP2006527756A (ja) *	2003-06-19	2006-12-07	ファイザー・プロダクツ・インク	Ｎｋ１拮抗薬
US20060148783A1 (en) *	2003-11-10	2006-07-06	Lundeen James E	Method and medicine for treating gastrointestinal disorder including fecal incontinence
US20070142367A1 (en) *	2003-11-10	2007-06-21	Lundeen James E	Method and medicine for treating gastrointestinal disorder including fecal incontinence
US20060148782A1 (en) *	2003-11-10	2006-07-06	Lundeen James E	Method and medicine for treating a mammal presenting urinary incontinence, urinary urgency, or both
US20060148781A1 (en) *	2003-11-10	2006-07-06	Lundeen James E	Method and medicine for treating gastrointestinal disorder in a non-human mammal
US20050113365A1 (en) *	2003-11-10	2005-05-26	Sir Isaac Newton Enterprises Llc	Method and medicine for treating gastrointestinal disorder including irritable bowel syndrome
JPWO2005051912A1 (ja) *	2003-11-28	2007-12-06	田辺三菱製薬株式会社	ピペリジン化合物およびその製法
CA2552965A1 (en) *	2004-01-14	2005-07-28	Takeda Pharmaceutical Company Limited	Carboxamide derivative and use thereof
TW200730494A (en) *	2005-10-10	2007-08-16	Glaxo Group Ltd	Novel compounds
ATE472529T1 (de) *	2005-10-10	2010-07-15	Glaxo Group Ltd	Prolinamidderivate als natriumkanalmodulatoren
US20100009983A1 (en) *	2006-05-09	2010-01-14	Braincells, Inc.	5 ht receptor mediated neurogenesis
JP4904945B2 (ja)	2006-06-30	2012-03-28	セントラル硝子株式会社	光学活性１−（フルオロ、トリフルオロメチルまたはトリフルオロメトキシ置換フェニル）アルキルアミンｎ−モノアルキル誘導体の製造方法
GB0621229D0 (en) *	2006-10-20	2006-12-06	Glaxo Group Ltd	Novel use
WO2008090117A1 (en)	2007-01-24	2008-07-31	Glaxo Group Limited	Pharmaceutical compositions comprising 3, 5-diamin0-6- (2, 3-dichl0phenyl) -l, 2, 4-triazine or r (-) -2, 4-diamino-5- (2, 3-dichlorophenyl) -6-fluoromethyl pyrimidine and an nk1
JP5510040B2 (ja) *	2010-04-28	2014-06-04	セントラル硝子株式会社	光学活性（ｒ）−１−（４−フルオロフェニル）エチルアミンを得る光学分割
WO2012175434A1 (en)	2011-06-20	2012-12-27	Glaxo Group Limited	Pharmaceutical formulations comprising vestipitant
US9782397B2 (en)	2011-07-04	2017-10-10	Irbm Science Park S.P.A.	Treatment of corneal neovascularization
JP6111274B2 (ja)	2012-02-22	2017-04-05	レオファーマアクティーゼルスカブ	新規ニューロキニン１受容体アンタゴニスト化合物
WO2015024203A1 (en)	2013-08-20	2015-02-26	Leo Pharma A/S	Novel neurokinin 1 receptor antagonist compounds ii
WO2016102967A1 (en)	2014-12-23	2016-06-30	Convergence Pharmaceuticals Limited	Process for preparing alpha-carboxamide pyrrolidine derivatives
CN108368062A (zh) *	2015-12-07	2018-08-03	橘生药品工业株式会社	Nk1受体拮抗剂
IL269875B2 (en)	2017-04-10	2024-06-01	Chase Therapeutics Corp	NK1 antagonist combination and a method for the treatment of synucleinopathies
MA49524A (fr)	2017-06-30	2021-05-26	Chase Therapeutics Corp	Compositions d'antagoniste de nk-1 et méthodes destinées à être utilisées dans le traitement de la dépression
SG11202002706XA (en)	2017-10-05	2020-04-29	Biogen Inc	Process for preparing alpha-carboxamide pyrolidine derivatives

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4379152A (en)	1974-05-09	1983-04-05	Toyama Chemical Co., Ltd.	Cephalosporins
US4219554A (en)	1974-05-09	1980-08-26	Toyama Chemical Company, Limited	Novel penicillins and cephalosporins and process for producing same
US4327097A (en)	1974-05-09	1982-04-27	Toyama Chemical Co., Ltd.	Novel penicillins
US4110327A (en)	1974-05-09	1978-08-29	Toyama Chemical Co., Ltd.	2,3 Diketo-piperazinocarbonylamino alkanoic acids and derivatives
US4410522A (en)	1974-05-09	1983-10-18	Toyama Chemical Co., Ltd.	Cephalosporins
US4087424A (en)	1974-05-09	1978-05-02	Toyama Chemical Co., Ltd.	Novel penicillins and cephalosporins and process for producing the same
IL47168A (en)	1974-05-09	1979-07-25	Toyama Chemical Co Ltd	Mono or dioxo piperazino(thio)carbonylamino derivatives ofpenicillins and cephalosporins and process for producing the same
US4112090A (en)	1974-05-09	1978-09-05	Toyama Chemical Co., Ltd.	Novel penicillins and cephalosporins and process for producing the same
NO154582C (no) *	1978-10-20	1986-11-05	Ferrosan Ab	Analogifremgangsmaate for fremstilling av terapeutisk aktive difenyl-dibutylpiperazinkarboksamider.
JPS57118587A (en)	1981-11-26	1982-07-23	Toyama Chem Co Ltd	Novel penicillin
US5028610A (en)	1987-03-18	1991-07-02	Sankyo Company Limited	N-benzhydryl-substituted heterocyclic derivatives, their preparation and their use
GB8709666D0 (en)	1987-04-23	1987-05-28	Beecham Group Plc	Compounds
GB8713061D0 (en)	1987-06-04	1987-07-08	Beecham Group Plc	Compounds
US5109014A (en)	1990-12-10	1992-04-28	Jacobson Richard M	N-aryl-3-aryl-4-substituted-2,3,4,5-tetrahydro-1H-pyrazole-1-carboxamides
SE9100860D0 (sv)	1991-03-22	1991-03-22	Kabi Pharmacia Ab	New use
EP0533280B2 (en)	1991-09-20	2004-12-01	Glaxo Group Limited	Novel medical use for tachykinin antagonists
CA2083891A1 (en)	1991-12-03	1993-06-04	Angus Murray Macleod	Heterocyclic compounds, compositions containing them and their use in therapy
US5563127A (en)	1993-03-24	1996-10-08	The Dupont Merck Pharmaceutical Company	Boronic acid and ester inhibitors of thrombin
US5348955A (en)	1993-06-22	1994-09-20	Merck & Co., Inc.	N,N-diacylpiperazines
IL111730A (en)	1993-11-29	1998-12-06	Fujisawa Pharmaceutical Co	Piperazine derivatives, processes for their preparation and pharmaceutical preparations containing them
IL112778A0 (en)	1994-03-04	1995-05-26	Merck & Co Inc	Substituted heterocycles, their preparation and pharmaceutical compositions containing them
US5464788A (en)	1994-03-24	1995-11-07	Merck & Co., Inc.	Tocolytic oxytocin receptor antagonists
DE4425146A1 (de)	1994-07-15	1996-01-18	Basf Ag	Verwendung heterocyclischer Verbindungen
AU3085895A (en)	1994-07-26	1996-02-22	Sankyo Company Limited	N-phenylated amide and urea derivatives
US5696123A (en)	1994-09-17	1997-12-09	Boehringer Ingelheim Kg	Neurokinin antagonists
DE19520499C2 (de)	1994-09-17	2003-06-18	Boehringer Ingelheim Kg	Neurokinin-Antagonisten, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende pharmazeutische Zusammensetzungen sowie ihre Verwendung
EP0709375B1 (en)	1994-10-25	2005-05-18	AstraZeneca AB	Therapeutic heterocycles
US5998444A (en)	1995-10-24	1999-12-07	Zeneca Ltd.	Piperidinyl compounds as NK1 or NK2 antagonists
US5629322A (en)	1994-11-15	1997-05-13	Merck & Co., Inc.	Cyclic amidine analogs as inhibitors of nitric oxide synthase
US5576317A (en)	1994-12-09	1996-11-19	Pfizer Inc.	NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis
US5700801A (en)	1994-12-23	1997-12-23	Karl Thomae, Gmbh	Piperazine derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them
PL321003A1 (en)	1994-12-23	1997-11-24	Thomae Gmbh Dr K	Derivatives of piperasine, drugs containing them, their application and methods of obtaining them
NZ321575A (en)	1995-10-30	1999-05-28	Janssen Pharmaceutica Nv	1-(1,2-disubstituted piperidinyl)-4- substituted piperazine derivatives
DE19608665A1 (de)	1996-03-06	1997-09-11	Boehringer Ingelheim Kg	Neue Arylglycinamidderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
US6057323A (en)	1996-03-08	2000-05-02	Adolor Corporation	Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith
US5859012A (en)	1996-04-03	1999-01-12	Merck & Co., Inc.	Inhibitors of farnesyl-protein transferase
JP2000507582A (ja)	1996-04-03	2000-06-20	メルクエンドカンパニーインコーポレーテッド	ファルネシルプロテイントランスフェラーゼの阻害剤
WO1997036592A1 (en)	1996-04-03	1997-10-09	Merck & Co., Inc.	Inhibitors of farnesyl-protein transferase
EP0891349A4 (en)	1996-04-03	2001-01-24	Merck & Co Inc	FARNESYL-PROTEIN TRANSFERASE INHIBITORS
AU3359697A (en)	1996-07-08	1998-02-02	Yamanouchi Pharmaceutical Co., Ltd.	Bone resorption inhibitors
US6274604B1 (en) *	1996-07-17	2001-08-14	Merck & Co., Inc.	Alteration of circadian rhythmicity with a tachykinin antagonist
US6117855A (en)	1996-10-07	2000-09-12	Merck Sharp & Dohme Ltd.	Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
US5929077A (en)	1996-11-08	1999-07-27	Leftheris; Katerina	Thioproline-containing inhibitors of farnesyl protein transferase
US6114315A (en)	1996-12-02	2000-09-05	Merck Sharp & Dohme Ltd.	Use of NK-1 receptor antagonists for treating major depressive disorders with anxiety
US5977104A (en)	1996-12-02	1999-11-02	Merck Sharp & Dohme Ltd.	Use of NK-1 receptor antagonists for treating bipolar disorders
JP2001504852A (ja)	1996-12-02	2001-04-10	メルクシヤープエンドドームリミテツド	双極性障害の治療のためのｎｋ−１受容体拮抗薬の使用
AUPO735997A0 (en)	1997-06-17	1997-07-10	Fujisawa Pharmaceutical Co., Ltd.	Piperazine derivatives
WO1999009985A1 (en)	1997-08-27	1999-03-04	Merck & Co., Inc.	Inhibitors of prenyl-protein transferase
JP2001524465A (ja)	1997-11-24	2001-12-04	メルクエンドカムパニーインコーポレーテッド	細胞接着阻害剤としての置換β−アラニン誘導体
HUP0203651A2 (en) *	1998-12-14	2003-02-28	Fujisawa Pharmaceutical Co	Piperazine derivatives
GB9923748D0 (en) *	1999-10-07	1999-12-08	Glaxo Group Ltd	Chemical compounds
WO2001030348A1 (en) *	1999-10-25	2001-05-03	Janssen Pharmaceutica N.V.	Use of substance p antagonists for influencing the circadian timing system
GB0025354D0 (en)	2000-10-17	2000-11-29	Glaxo Group Ltd	Chemical compounds
US20030022891A1 (en)	2000-12-01	2003-01-30	Anandan Palani	MCH antagonists and their use in the treatment of obesity
MY141736A (en)	2002-10-08	2010-06-15	Elanco Animal Health Ireland	Substituted 1,4-di-piperidin-4-yi-piperazine derivatives and their use as neurokinin antagonists

1999
- 1999-10-07 GB GBGB9923748.9A patent/GB9923748D0/en not_active Ceased
2000
- 2000-10-05 US US10/089,964 patent/US6951861B1/en not_active Expired - Lifetime
- 2000-10-05 PT PT04076632T patent/PT1460066E/pt unknown
- 2000-10-05 CO CO00075822A patent/CO5251467A1/es active IP Right Grant
- 2000-10-05 ES ES00969414T patent/ES2222927T3/es not_active Expired - Lifetime
- 2000-10-05 DE DE60040176T patent/DE60040176D1/de not_active Expired - Lifetime
- 2000-10-05 TR TR2002/00936T patent/TR200200936T2/xx unknown
- 2000-10-05 ES ES04076650T patent/ES2312917T3/es not_active Expired - Lifetime
- 2000-10-05 NZ NZ531127A patent/NZ531127A/en not_active IP Right Cessation
- 2000-10-05 AT AT00969414T patent/ATE270664T1/de active
- 2000-10-05 SI SI200031010T patent/SI1454901T1/sl unknown
- 2000-10-05 JP JP2001528165A patent/JP4776844B2/ja not_active Expired - Fee Related
- 2000-10-05 DK DK04076632T patent/DK1460066T3/da active
- 2000-10-05 CA CA2386515A patent/CA2386515C/en not_active Expired - Lifetime
- 2000-10-05 CZ CZ20021166A patent/CZ302340B6/cs not_active IP Right Cessation
- 2000-10-05 SI SI200031037T patent/SI1460066T1/sl unknown
- 2000-10-05 KR KR1020077026231A patent/KR100857671B1/ko not_active IP Right Cessation
- 2000-10-05 PL PL356261A patent/PL201191B1/pl unknown
- 2000-10-05 BR BR0014541-6A patent/BR0014541A/pt not_active Application Discontinuation
- 2000-10-05 AT AT04076632T patent/ATE435215T1/de active
- 2000-10-05 MY MYPI20004668A patent/MY130907A/en unknown
- 2000-10-05 KR KR1020027004438A patent/KR100817373B1/ko not_active IP Right Cessation
- 2000-10-05 PT PT04076650T patent/PT1454901E/pt unknown
- 2000-10-05 EP EP04076632A patent/EP1460066B1/en not_active Expired - Lifetime
- 2000-10-05 ES ES04076632T patent/ES2329130T3/es not_active Expired - Lifetime
- 2000-10-05 DE DE60042501T patent/DE60042501D1/de not_active Expired - Lifetime
- 2000-10-05 CN CNB008158606A patent/CN100413850C/zh not_active Expired - Fee Related
- 2000-10-05 DK DK04076650T patent/DK1454901T3/da active
- 2000-10-05 AT AT04076650T patent/ATE407125T1/de active
- 2000-10-05 HU HU0203136A patent/HUP0203136A3/hu unknown
- 2000-10-05 SI SI200030492T patent/SI1218359T1/xx unknown
- 2000-10-05 EP EP04076650A patent/EP1454901B1/en not_active Expired - Lifetime
- 2000-10-05 WO PCT/EP2000/009722 patent/WO2001025219A2/en active IP Right Grant
- 2000-10-05 IL IL14896400A patent/IL148964A0/xx active IP Right Grant
- 2000-10-05 MX MXPA02003515A patent/MXPA02003515A/es active IP Right Grant
- 2000-10-05 DK DK00969414T patent/DK1218359T3/da active
- 2000-10-05 NZ NZ518144A patent/NZ518144A/xx not_active IP Right Cessation
- 2000-10-05 EP EP00969414A patent/EP1218359B1/en not_active Expired - Lifetime
- 2000-10-05 AU AU79139/00A patent/AU768780B2/en not_active Ceased
- 2000-10-05 DE DE60012031T patent/DE60012031T2/de not_active Expired - Lifetime
- 2000-10-05 PT PT00969414T patent/PT1218359E/pt unknown
- 2000-10-06 AR ARP000105284A patent/AR025975A1/es not_active Application Discontinuation
- 2000-10-06 PE PE2000001068A patent/PE20010741A1/es not_active Application Discontinuation
- 2000-10-06 TN TNTNSN00194A patent/TNSN00194A1/en unknown
- 2000-10-07 TW TW089121014A patent/TWI225485B/zh not_active IP Right Cessation
2002
- 2002-04-01 IL IL148964A patent/IL148964A/en not_active IP Right Cessation
- 2002-04-03 ZA ZA200202589A patent/ZA200202589B/en unknown
- 2002-04-05 NO NO20021637A patent/NO323776B1/no not_active IP Right Cessation
- 2002-07-03 US US10/190,170 patent/US6642240B2/en not_active Ceased
2003
- 2003-07-03 HK HK03104740.2A patent/HK1052506B/zh not_active IP Right Cessation
- 2003-08-08 US US10/637,825 patent/US7071196B2/en not_active Expired - Fee Related
2004
- 2004-05-04 US US10/838,838 patent/US20040209893A1/en not_active Abandoned
- 2004-11-06 HK HK04108748A patent/HK1065798A1/xx not_active IP Right Cessation
- 2004-12-01 HK HK04109454.6A patent/HK1066537A1/xx not_active IP Right Cessation
2006
- 2006-01-18 US US11/334,267 patent/US7345041B2/en not_active Expired - Fee Related
2007
- 2007-12-13 US US11/955,847 patent/US7625904B2/en not_active Expired - Fee Related
2008
- 2008-11-27 CY CY20081101376T patent/CY1110172T1/el unknown
2009
- 2009-09-18 CY CY20091100969T patent/CY1110104T1/el unknown
2010
- 2010-07-15 AR ARP100102567A patent/AR077414A2/es unknown

Also Published As

Publication number	Publication date
HUP0203136A2 (hu)	2003-02-28
ZA200202589B (en)	2003-08-27
US20060122192A1 (en)	2006-06-08
GB9923748D0 (en)	1999-12-08
AU7913900A (en)	2001-05-10
CN1391564A (zh)	2003-01-15
ES2222927T3 (es)	2005-02-16
DE60042501D1 (de)	2009-08-13
CY1110172T1 (el)	2015-01-14
US6951861B1 (en)	2005-10-04
CZ20021166A3 (cs)	2002-11-13
ES2312917T3 (es)	2009-03-01
EP1218359B1 (en)	2004-07-07
AU768780B2 (en)	2004-01-08
PT1218359E (pt)	2004-10-29
KR20020038800A (ko)	2002-05-23
TR200200936T2 (tr)	2002-07-22
CY1110104T1 (el)	2015-01-14
DK1460066T3 (da)	2009-11-02
TNSN00194A1 (en)	2005-11-10
US7071196B2 (en)	2006-07-04
BR0014541A (pt)	2002-09-17
AR077414A2 (es)	2011-08-24
US20040209893A1 (en)	2004-10-21
CO5251467A1 (es)	2003-02-28
SI1218359T1 (en)	2005-02-28
NZ531127A (en)	2005-11-25
EP1460066A1 (en)	2004-09-22
NO20021637L (no)	2002-06-06
SI1460066T1 (sl)	2009-12-31
TWI225485B (en)	2004-12-21
HK1066537A1 (en)	2005-03-24
JP2003511377A (ja)	2003-03-25
PL356261A1 (en)	2004-06-28
PT1460066E (pt)	2009-09-10
WO2001025219A2 (en)	2001-04-12
HK1052506B (zh)	2008-12-19
US20080249108A1 (en)	2008-10-09
SI1454901T1 (sl)	2009-02-28
NZ518144A (en)	2004-04-30
PL201191B1 (pl)	2009-03-31
ES2329130T3 (es)	2009-11-23
US6642240B2 (en)	2003-11-04
ATE270664T1 (de)	2004-07-15
CN100413850C (zh)	2008-08-27
DE60012031D1 (de)	2004-08-12
ATE407125T1 (de)	2008-09-15
DK1218359T3 (da)	2004-10-18
EP1218359A2 (en)	2002-07-03
US20030028021A1 (en)	2003-02-06
MY130907A (en)	2007-07-31
CZ302340B6 (cs)	2011-03-23
MXPA02003515A (es)	2002-09-02
PE20010741A1 (es)	2001-07-18
KR100857671B1 (ko)	2008-09-08
HUP0203136A3 (en)	2003-03-28
IL148964A (en)	2007-02-11
EP1454901B1 (en)	2008-09-03
EP1454901A1 (en)	2004-09-08
CA2386515A1 (en)	2001-04-12
EP1460066B1 (en)	2009-07-01
US7345041B2 (en)	2008-03-18
DK1454901T3 (da)	2009-01-12
ATE435215T1 (de)	2009-07-15
WO2001025219A3 (en)	2001-12-13
HK1052506A1 (en)	2003-09-19
NO20021637D0 (no)	2002-04-05
DE60040176D1 (de)	2008-10-16
PT1454901E (pt)	2008-12-12
KR20070112308A (ko)	2007-11-22
KR100817373B1 (ko)	2008-03-27
AR025975A1 (es)	2002-12-26
CA2386515C (en)	2011-06-07
NO323776B1 (no)	2007-07-02
JP4776844B2 (ja)	2011-09-21
US7625904B2 (en)	2009-12-01
HK1065798A1 (en)	2005-03-04
DE60012031T2 (de)	2005-07-07
US20040048862A1 (en)	2004-03-11

Publication	Publication Date	Title
IL148964A0 (en)	2002-11-10	Piperazine compounds
PL352911A1 (en)	2003-09-22	New compounds
GB2357761B (en)	2001-09-05	Compounds
GB9904933D0 (en)	1999-04-28	Compounds
PL354360A1 (en)	2004-01-12	New compounds
PL356140A1 (en)	2004-06-14	New compounds
GB9908828D0 (en)	1999-06-16	Compounds
GB9902399D0 (en)	1999-03-24	Compounds
GB9904930D0 (en)	1999-04-28	Thiazoloindolinone compounds
GB9905771D0 (en)	1999-05-05	Compounds
HUP9904624D0 (en)	2000-02-28	New compounds
SI1202994T1 (en)	2004-10-31	New compounds
GB9903291D0 (en)	1999-04-07	Compounds
GB9909840D0 (en)	1999-06-23	Compounds
GB9907456D0 (en)	1999-05-26	Compounds
GB9906278D0 (en)	1999-05-12	Compounds
GB9909474D0 (en)	1999-06-23	Compounds
GB9909802D0 (en)	1999-06-23	Compounds
GB9909803D0 (en)	1999-06-23	Compounds
GB9903420D0 (en)	1999-04-07	Compounds
GB9903296D0 (en)	1999-04-07	Compounds
GB9909839D0 (en)	1999-06-23	Compounds
GB9903290D0 (en)	1999-04-07	Compounds
GB9910146D0 (en)	1999-06-30	Compounds
GB9903280D0 (en)	1999-04-07	Compounds

Legal Events

Date	Code	Title	Description
2007-07-24	FF	Patent granted
2007-08-19	KB	Patent renewed